Four ways in which GLP-1 medication for weight loss is changing the diabetes treatment paradigm

The landscape of diabetes care and medication is changing, and GLP-1 for weight loss is becoming more popular than ever. With its dual impact on blood sugar and body weight, these drugs are reshaping what “diabetes medication” means, especially for patients with obesity or metabolic syndrome. GLP-1 medications used for weight loss are driving a paradigm shift in how doctors diagnose, manage, and prevent type 2 diabetes and its related complications. 

Below, Dr. Alexander Shapsis of EndoSlim Clinic at Atlantic Gastroenterology dives into four key ways in which this shift is affecting those with diabetes:

1. GLP-1s have become first-line therapy for type 2 diabetes

Traditionally, the first-line treatment for newly diagnosed type 2 diabetes has been inexpensive generics, but that is changing. According to a recent analysis by IQVIA, first-time prescriptions for GLP-1 therapies have surged from a mere 3% of diabetes patients in 2021 to nearly 25% by early 2025. This dramatic rise reflects updated clinical guidelines from the American Diabetes Association (ADA), which now recommend GLP-1 receptor agonists as first-line therapy for many patients.

2. Dual benefit includes improved glycemic control plusweight loss

One of the most powerful factors driving GLP-1 adoption is its unique ability to tackle both high blood sugar and excess weight. GLP-1 receptor agonists enhance insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite, all mechanisms that help control glucose while also promoting satiety and caloric reduction. This dual effect is especially meaningful for the many patients whose type 2 diabetes is tied to obesity or metabolic syndrome.

3. Broadening use beyond diabetes in tackling comorbidities

Perhaps most transformative is that GLP-1 therapies are no longer confined to diabetes alone. Many providers are increasingly prescribing them for patients with overlapping conditions such as obesity, cardiovascular risk, kidney disease, and more. This shift is supported by growing evidence that GLP-1s deliver “multi-system” benefits, from improved metabolic markers to reductions in cardiovascular risk, kidney disease progression, and other comorbidities common in people with type 2 diabetes or obesity.

4. Changing provider and patient behavior

The rapid uptake of GLP-1s reflects a broader shift in how both physicians and patients view metabolic disease. Instead of waiting until advanced disease stages or after other therapies fail, GLP-1s are increasingly being used early, sometimes even at diagnosis. This early adoption is reshaping the treatment journey for many.

Learn more about GLP-1 for weight loss!

If you live in Brooklyn or the surrounding area, now may be a good time to consider whether GLP-1 therapy could be appropriate. As a physician specializing in gastroenterology and digestive health, Dr. Alexander Shapsis is in a unique position to evaluate how weight, metabolic health, and gastrointestinal wellness intersect. Contact EndoSlim Clinic at Atlantic Gastroenterology in Brooklyn, New York, to schedule a consultation visit with our team.

Share this Article